
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals has demonstrated substantial growth, primarily driven by strong sales of its product LIVMARLI, which recorded $88.1 million in revenue during 2Q25, reflecting an impressive 87% year-over-year increase. The company has increased its 2025 revenue guidance to a range of $490 million to $510 million, up from a previous estimate of $435 million to $450 million, indicating robust commercial momentum and positive market response. Furthermore, the total revenues for 2Q25 reached $127.8 million, a 64% year-over-year increase, showcasing the company’s strong performance and higher-than-expected adoption rates for its therapies.
Bears say
Mirum Pharmaceuticals faces significant commercial risk due to its dependence on non-composition of matter patent coverage for maralixibat, which may hinder its competitive position in a crowded market of ASBT inhibitors. The company’s revenue remains in an early growth phase, and potential competition or slower sales growth may impede its path to profitability. Additionally, the recent loss from the termination of a revenue interest purchase agreement highlights financial vulnerabilities, and the inherent volatility of biotech stocks amplifies the downside risk associated with clinical trial outcomes and market dynamics.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares